Transformational cell therapies for patients with pancreatic disease

Koligo experts share latest thinking. Relevant studies, outcomes and assessments.

The people, science and innovative mindset to forever improve the lives of people we touch.

OUR MISSION

Koligo Therapeutics’ mission is to develop, manufacture, and commercialize transformative cell therapies for the treatment of pancreatic diseases.

VALUES

We respect patients and healthcare professionals. We respect our colleagues and co-workers. We are transparent to regulators and the scientific community. We protect information, our intellectual property and our assets. We do not compromise our integrity.

CODE OF ETHICS AND CONDUCT

Koligo is dedicated to supporting our mission while respecting our values. Our employees agree in writing to certain professional standards to codify our mutual understanding of Koligo’s ethics and conduct. Our current professional standards agreement includes the following commitments from all of Koligo’s employees:

  • I will, at all times, ensure that the protection of the safety and well-being of patients (e.g. study subjects or end consumers of the company’s products) is the primary guiding principle in my work, without regard to other potentially conflicting obligations.
  • I agree to comply with all laws and regulations applicable to my job duties, including those of the United States Food and Drug Administration, the European Medicines Evaluation Agency, and all other competent regulatory bodies.
  • I agree to comply with Koligo’s current effective Standard Operating Procedures.
  • I agree to comply with industry and professional standards applicable to my job responsibilities.
  • I agree to respect and maintain the information and property of Koligo and use such information and property only as it is intended and as instructed.
  • I will treat all coworkers, consultants, doctors, investigators, vendors and other colleagues with respect and without prejudice, regardless of religion, race, gender, ethnicity, or other factors immaterial to a person’s job performance.
  • I agree to comply with the requirements imposed on Koligo under Health Insurance Portability and Accountability Act, including as to the disclosure any patient protected information.
  • I represent that at no time have I been disqualified or debarred by the United States Food and Drug Administration.

Kyslecel personalized cell therapy for chronic pancreatitis. Because pain should not define your life.